Noxopharm (ASX:NOX) releases DARRT-1 study clinical data

[videojs_hls url=’//du7x25at22z7c.cloudfront.net/274850/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/Headlines04_360_191220.jpg’]

Clinical drug development company Noxopharm (ASX:NOX) has released DARRT-1 study clinical data.

The Company says the “DARRT program delivers strong anti-cancer response in 47 per cent of men with late-stage prostate cancer”.

An independent oncologist, Professor Paul de Souza, has confirmed the significance of this high response rate.

The company hopes that the “promising new therapy” will meet a “major unmet need in prostate cancer”.

The planned adaptive design Phase 2 study is expected to be the final step before gaining marketing approval.

Shares in Noxopharm (ASX:NOX) are trading 1.61 per cent higher at 32 cents.
Copyright 2019 – Finance News Network

Source: Finance News Network